NEW RESEARCH OFFERS INSIGHT INTO METABOLOMICS METHODS
Publication Details Technology for the Simultaneous Quantification and Qualification of Metabolites
RESEARCH TRIANGLE PARK, N.C. (July 29, 2009) — Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced the publication of a paper describing Metabolonís biochemical profiling technology. The paper, titled "Integrated, Nontargeted Ultrahigh Performance Liquid Chromatography/Electrospray Ionization Tandem Mass Spectrometry Platform for the Identification and Relative Quantification of the Small-Molecule Complement of Biological Systems", appears in Analytical Chemistry.
"This paper describes a general method of profiling biochemicals in a high-throughput and scalable manner which enables the simultaneous quantification and identification of metabolites," explained Anne M. Evans, Ph.D., senior research scientist with Metabolon and lead author of the publication.
The system described in the paper is an integral part of Metabolonís commercial metabolomics platform. In addition to the UHPLC-MS/MS system, Metabolon employs a GC-MS system to provide additional breadth of coverage of biochemicals and metabolites.
Specific challenges associated with metabolomics analyses addressed in this paper include:
Click here to read the complete abstract of the publication
Metabolon is a diagnostics and services company offering the industryís leading biochemical profiling platform. Metabolonís patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.